Puma Biotechnology (PBYI) Gross Margin (2017 - 2026)
Puma Biotechnology (PBYI) reported Gross Margin of 76.74% for Q1 2026, down 32.0% on a YoY basis from 112.85% in Q1 2025, and up 10.66% quarter-over-quarter from 69.35% in Q4 2025.
Puma Biotechnology (PBYI) Gross Margin (2017 - 2026) Analysis & Trends
Puma Biotechnology has reported Gross Margin for 10 years, with the latest figure at 76.74% in Q1 2026.
- For the quarter ending Q1 2026, Gross Margin fell 32.0% year-over-year to 76.74%; the trailing twelve-month figure through Mar 2026 stood at 74.46% (up 206.0% YoY), and the FY2025 full-year result was 74.53%, up 248.0% from the prior year.
- Gross Margin for Q1 2026 stood at 76.74%, up from 69.35% in the prior quarter.
- The five-year high for Gross Margin was 80.79% in Q4 2022, with the low at 63.87% in Q3 2024.
- Historically, Gross Margin has averaged 75.09% across 5 years, with a median of 76.44% in 2024.
- Annual changes were most pronounced in 2023 — Gross Margin slumped 1449 bps — and 2025, when it jumped 1378 bps.
- Puma Biotechnology's Gross Margin stood at 80.79% in 2022, then dropped by 18 bps to 66.3% in 2023, then grew by 15 bps to 76.44% in 2024, then fell by 9 bps to 69.35% in 2025, then rose by 11 bps to 76.74% in 2026.
- The last three Gross Margin figures came in at 76.74% (Q1 2026), 69.35% (Q4 2025), and 77.65% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 79.04% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 86.85% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Puma Biotechnology | 384.39 Mn | 282.84 Mn | 34.39 Mn | 76.74% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 76.74% |
| Dec 31, 2025 | 69.35% |
| Sep 30, 2025 | 77.65% |
| Jun 30, 2025 | 76.54% |
| Mar 31, 2025 | 77.06% |
| Dec 31, 2024 | 76.44% |
| Sep 30, 2024 | 63.87% |
| Jun 30, 2024 | 77.36% |
| Mar 31, 2024 | 75.49% |
| Dec 31, 2023 | 66.30% |
| Sep 30, 2023 | 76.33% |
| Jun 30, 2023 | 78.27% |
| Mar 31, 2023 | 74.95% |
| Dec 31, 2022 | 80.79% |
| Sep 30, 2022 | 78.12% |
| Jun 30, 2022 | 74.94% |
| Mar 31, 2022 | 76.29% |
| Dec 31, 2021 | 78.51% |
| Sep 30, 2021 | 77.77% |
| Jun 30, 2021 | 77.58% |